

6<sup>th</sup> March, 2024

- |   |  |
|---|--|
| <p>(1) BSE Limited<br/>Listing Department,<br/>Phiroze Jeejeebhoy Towers,<br/>Dalal Street,<br/>Mumbai 400 001</p> <p><b>Scrip Code: 500087</b></p> | <p>(2) National Stock Exchange of India Limited<br/>Listing Department<br/>Exchange Plaza, 5<sup>th</sup> floor,<br/>Plot no. C/1, G Block,<br/>Bandra Kurla Complex,<br/>Bandra (East), Mumbai - 400 051</p> <p><b>Scrip Code: CIPLA EQ</b></p> |
| <p>(3) SOCIETE DE LA BOURSE DE LUXEMBOURG<br/>Societe Anonyme<br/>35A Boulevard Joseph II,<br/>L-1840 Luxembourg</p>                                |  |

**Sub: Disclosure under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)**

Dear Sir/Madam,

In compliance with the provisions of Regulation 30 of the SEBI Listing Regulations, we hereby notify that Goldencross Pharma Limited, wholly owned subsidiary (“Goldencross”) of the Company has completed the sale of its entire shareholding in Wellthy Therapeutics Private Limited (“Wellthy”) in terms of the definitive agreement executed on 6<sup>th</sup> March, 2024.

Details required to be disclosed under the SEBI Listing Regulations read with SEBI Circular no. SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated 13<sup>th</sup> July 2023, have been provided in Annexure – I to this letter.

Please take the above information on record.

Yours faithfully,  
**For Cipla Limited**

**Rajendra Chopra**  
**Company Secretary**

Prepared by: Muskan Jain

**Annexure – I**

Details required to be disclosed as per SEBI circular No. SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123  
dated 13<sup>th</sup> July 2023

Sr. No.	Particulars	Details
a)	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year;	Not applicable as Wellthy is neither unit or division or undertaking or subsidiary or associate company of the Company.
b)	Date on which the agreement for sale has been entered into;	Goldencross entered into a definitive agreement for the sale of its entire stake in Wellthy on 6 <sup>th</sup> March, 2024, and completed the sale on the same date.
c)	The expected date of completion of sale/disposal;	
d)	Consideration received from such sale/disposal;	Consideration of ~INR 59.71 lakh was received for the sale of 5,32,121 Compulsorily Convertible Preference Shares (CCPS) and 10 Equity Shares held in Wellthy.
e)	Brief details of buyers and whether any of the buyers belong to the promoter/promoter group/group companies. If yes, details thereof;	Mr. Nikhil Shah is an Indian national and relative of Mr. Abhishek Shah, promoter of Wellthy.  He does not belong to the promoter/promoter group/group companies of the Company.
f)	Whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length”;	No.
g)	Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations.	Not Applicable.
h)	Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.	Not Applicable.